Cleveland Clinic’s Endocrinology & Metabolism Institute is working to offer novel opportunities and therapies with diabetes and kidney disease.
A New Era of Management for Diabetic Kidney Disease
A Cleveland Clinic nephrologist discusses the landmark studies that have enabled the availability of new treatment options for managing diabetic kidney disease.
SGLT-2 Inhibitors: A New Era in Managing Diabetic Kidney Disease Starts Now
SGLT-2 inhibitors have emerged as a major addition to the nephrology toolkit in the management of diabetic kidney disease.